false 0001211583 0001211583 2024-06-25 2024-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549


Form 8-K


Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 25, 2024



(Exact name of registrant as specified in its charter)



(Commission File Number)


British Columbia, Canada   20-0442384

(State or other jurisdiction of


  (I.R.S. Employer Identification No.)


PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC




(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (919) 636-4530


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Title of each class Trading symbol(s) Name of each exchange on which
Common FENC, FRX Nasdaq, TSX





Item 5.07Submission of Matters to a Vote of Security Holders.


On June 25, 2024, Fennec Pharmaceuticals Inc. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:


1.               The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:


Name of Nominee  Votes For  Votes Withheld  Broker Non-Votes
Dr. Khalid Islam  10,100,238  371,270  6,091,979
Chris A. Rallis  9,688,517  782,991  6,091,979
Marco Brughera  9,801,305  670,203  6,091,979
Jodi Cook  8,991,182  1,480,326  6,091,979
Rostislav Raykov  9,859,679  611,829  6,091,979


2.               The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:


Votes For  16,225,975
Votes Withheld  337,512
Votes Against  0
Broker Non-Votes  0


3.               The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:


Votes For  9,830,484
Votes Against  346,881
Abstentions  294,143
Broker Non-Votes  6,091,979







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date June 25, 2024 By: /s/ Rostislav Raykov
    Rostislav Raykov
    Chief Executive Officer